NEW YORK – Tel Aviv-based biopharmaceutical company VBL Therapeutics today announced plans to extend its ongoing Phase III OVAL trial to Japan through a licensing agreement with NanoCarrier. The global, randomized OVAL trial is evaluating VBL's drug, VB-111, in patients with platinum-resistant ovarian cancer.